(NewsDirect)
Futura Medical PLC CEO James Barder tellsProactive's Stephen Gunnion that 2023 was a pivotal year for thecompany as it rolled out its innovative sexual health product, Eroxon,designed to treat erectile dysfunction.
The over-the-counter availability of Eroxon distinguishes it asa groundbreaking product globally, facilitating easier access forconsumers without a prescription.
Barder noted the company reported significant achievements in2023, including revenue of £3.1 million and a strategic expansioninto the US market, bolstered by FDA approval and a partnership withleading OTC distributor Halen. This expansion is underscored bysuccessful launches in the UK and Belgium, capturing around a 20%market share.
Barder highlightedFutura's virtual organizational model and risk-mitigated marketingstrategy through partnerships focusing on advertising and promotionalspend. Looking ahead, Futura anticipates further global expansion withmore than ten country launches expected by April, surpassing initialforecasts.
Additionally, thecompany's vigilant stance against counterfeit products underscoresits commitment to safeguarding brand integrity and consumer trust.With new broker and investor relations appointments, Futura aims toenhance shareholder value and visibility.
ContactDetails
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2024 TheNewswire - All rights reserved.